Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Oncol Pharm Pract ; 27(7): 1753-1757, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33356885

ABSTRACT

INTRODUCTION: Cerebellar mutism syndrome (CMS) is a common complication after posterior fossa tumor resection. It is characterized by a significant lack or loss of speech. Its biological origin remains unclear and there are no standardized treatments. However, bromocriptine seems to be a possible treatment for this condition. CASE REPORT: In this paper, we present three cases of pediatric patients (4, 5, and 17-year old) who developed CMS after posterior fossa tumor surgery. They were treated with bromocriptine to improve neurological symptoms.Management and outcome: Bromocriptine was started at a low dose and was progressively increased to reach the minimum effective dose. After four months of treatment, a normal and fluid speech was observed in the three patients. No discontinuation due to adverse events were reported. DISCUSSION: Bromocriptine has shown to be an effective and safe treatment for CMS in pediatric patients after posterior fossa tumor resection.


Subject(s)
Cerebellar Neoplasms , Infratentorial Neoplasms , Medulloblastoma , Mutism , Bromocriptine/therapeutic use , Cerebellar Neoplasms/drug therapy , Cerebellar Neoplasms/surgery , Child , Humans , Mutism/drug therapy , Mutism/etiology , Postoperative Complications/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...